| Title |
Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma
|
|---|---|
| Published in |
Cancer Management and Research, February 2010
|
| DOI | 10.2147/cmar.s5009 |
| Pubmed ID | |
| Authors |
Frederick Lansigan, Diane M Stearns, Francine Foss |
| Abstract |
Denileukin diftitox (Ontak(®)) is indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL), a rare lymphoproliferative disorder of the skin. Denileukin diftitox was the first fusion protein toxin approved for the treatment of a human disease. This fusion protein toxin combines the IL2 protein with diphtheria toxin, and targets the CD25 subunit of the IL2 receptor, resulting in the unique delivery of a cytocidal agent to CD-25 bearing T-cells. Historically, immunotherapy targeting malignant T-cells including monoclonal antibodies has been largely ineffective as cytocidal agents compared to immunotherapy directed against B-cells such as rituximab. This review will summarize the development of denileukin diftitox, its proposed mechanism of action, the pivotal clinical trials that led to its FDA approval, the improvements in quality of life, and the common toxicities experienced during the treatment of patients with CTCL. CTCL is often a chronic progressive lymphoma requiring the sequential use of treatments such as retinoids, traditional chemotherapy, or biological response modifiers. The incorporation of the immunotoxin denileukin diftitox into the sequential or combinatorial treatment of CTCL will also be addressed. |
Mendeley readers
The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 11 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 3 | 27% |
| Student > Master | 2 | 18% |
| Student > Postgraduate | 1 | 9% |
| Student > Bachelor | 1 | 9% |
| Unknown | 4 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 4 | 36% |
| Medicine and Dentistry | 3 | 27% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 9% |
| Unknown | 3 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 November 2021.
All research outputs
#7,451,284
of 22,780,165 outputs
Outputs from Cancer Management and Research
#337
of 1,994 outputs
Outputs of similar age
#48,800
of 165,078 outputs
Outputs of similar age from Cancer Management and Research
#2
of 5 outputs
Altmetric has tracked 22,780,165 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,994 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 165,078 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.